1. MeiraGTx Holdings plc (NASDAQ:MGTX)
MeiraGTx Holdings plc (NASDAQ: MGTX) takes the No. 1 spot, and there was not much competition when the earnings surprise was measured in absolute dollars per share.
MeiraGTx Holdings plc (NASDAQ: MGTX) reported diluted EPS of $1.71 for the second quarter. Using the analyst consensus underlying this ranking, Wall Street had been expecting a loss of $0.44 per share, creating a massive $2.15 positive EPS surprise. Other market-data providers showed slightly different pre-report loss estimates, but all told the same basic story: analysts expected MeiraGTx Holdings plc (NASDAQ: MGTX) to lose money, and instead it reported a very large quarterly profit. Shares were around $13.52 in the ranking snapshot, up 6.67%.
The magnitude of the turnaround becomes clearer when looking beyond EPS.
MeiraGTx Holdings plc (NASDAQ: MGTX) reported second-quarter revenue of approximately $321.4 million, compared with just $3.7 million a year earlier. Net income attributable to ordinary shareholders reached $160.7 million, compared with a $38.8 million loss in the year-ago quarter. Basic EPS was $1.76 and diluted EPS was $1.71.
At first glance, that looks like the kind of commercial breakthrough biotechnology investors dream about. But this is where the details matter.
The enormous revenue increase did not come from hundreds of millions of dollars in newly launched drug sales. A substantial portion reflected licensing, collaboration and service revenue. MeiraGTx Holdings plc (NASDAQ: MGTX) recognized $204.6 million of related-party license revenue associated with licenses granted for certain programs, another $104.9 million of related-party service revenue, and $11.9 million of service revenue connected partly with manufacturing services provided under a collaboration with Eli Lilly.
That distinction is critical for investors evaluating the sustainability of the headline EPS number. Licensing and collaboration payments can create very large quarterly profits but may not recur at the same level every three months. The No. 1 ranking therefore reflects the magnitude of the earnings surprise, not a claim that $1.71 in quarterly EPS represents a new normal earnings run rate.
Still, the quarter was significant for reasons extending beyond accounting recognition.
MeiraGTx Holdings plc (NASDAQ: MGTX) is a clinical-stage genetic medicines company developing therapies across inherited retinal diseases, radiation-induced xerostomia, Parkinson’s disease and other conditions. During the quarter, the company acquired full rights to botaretigene sparoparvovec, commonly called bota-vec, from Johnson & Johnson and continued preparing for regulatory filings. It also received FDA Breakthrough Therapy Designation for AAV2-hAQP1, an experimental treatment targeting radiation-induced xerostomia.
The balance sheet improved significantly as well. Cash, cash equivalents and restricted cash stood at approximately $145.4 million at the end of June compared with $34.4 million a year earlier. MeiraGTx Holdings plc (NASDAQ: MGTX) also entered an agreement with Oberland Capital providing access to as much as $400 million in strategic investment, including substantial non-dilutive capital.
At the same time, research and development spending increased to $57.8 million from $33.5 million, reflecting the cost of pushing multiple genetic medicine programs forward and reacquiring rights to bota-vec. That is another reminder that biotechnology companies can have unusually volatile income statements as licensing deals, research spending, milestones and clinical-development investments move from quarter to quarter.
That volatility is precisely what made this earnings report such an outlier.
Wall Street went into the quarter expecting another loss from a clinical-stage biotechnology company. Instead, MeiraGTx Holdings plc (NASDAQ: MGTX) delivered more than $300 million in revenue, $160 million in quarterly net income and $1.71 in diluted EPS.
For investors searching for biotech stocks beating earnings estimates, gene therapy stocks, NASDAQ stocks to watch, biggest EPS surprises, Q2 earnings winners and stocks that crushed Wall Street expectations, MeiraGTx Holdings plc (NASDAQ: MGTX) produced the most dramatic earnings surprise in this ranking.
It was not merely an earnings beat. It was the kind of result that demonstrates why earnings season can still catch Wall Street completely off guard.
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
